PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer

Background: Chemotherapy is currently evaluated in order to enhance the efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer. However, the mechanisms by which these drugs could synergize with ICB remains unclear. The impact of chemotherapy on the PD-1/PD-L1 pathway and the resul...

Full description

Bibliographic Details
Main Authors: Magalie Dosset, Thaiz Rivera Vargas, Anaïs Lagrange, Romain Boidot, Frédérique Végran, Aurélie Roussey, Fanny Chalmin, Lucile Dondaine, Catherine Paul, Elodie Lauret Marie-Joseph, François Martin, Bernhard Ryffel, Christophe Borg, Olivier Adotévi, François Ghiringhelli, Lionel Apetoh
Format: Article
Language:English
Published: Taylor & Francis Group 2018-06-01
Series:OncoImmunology
Subjects:
chemotherapy
colorectal cancer, adaptive immune resistance
pd-1/pd-l1 pathway
immunotherapy
cd8 t cells
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1433981

Internet

http://dx.doi.org/10.1080/2162402X.2018.1433981

Similar Items